Mar 4, 2026 10:26AM
Mar 4, 2026 10:25AM
Dec 23, 2025 04:46PM
Dec 16, 2025 09:19AM
Nov 26, 2025 07:00AM
Jul 30, 2025 07:04AM
Jul 30, 2025 07:04AM Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Jul 28, 2025 12:24PM
Jul 28, 2025 12:24PM
Apr 14, 2025 02:29PM
Apr 14, 2025 02:28PM
Apr 14, 2025 08:00AM
Mar 24, 2025 09:00AM
Feb 18, 2025 07:00AM Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
Feb 10, 2025 07:10AM
Feb 5, 2025 07:00AM
Jan 27, 2025 07:00AM
Nov 4, 2024 07:08AM
Oct 18, 2024 09:11AM
Oct 18, 2024 09:06AM
Oct 7, 2024 07:00AM Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
Sep 16, 2024 07:00AM
Aug 29, 2024 08:15AM
Jul 17, 2024 07:00AM
Nov 21, 2023 01:53PM
Mar 13, 2023 07:00AM
Dec 28, 2022 07:01AM
Dec 28, 2022 07:00AM Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
Dec 8, 2022 07:00AM
Nov 25, 2022 07:00AM
Nov 2, 2022 07:15AM
Oct 25, 2022 07:00AM
Oct 13, 2022 07:00AM
Sep 12, 2022 07:00AM
Aug 25, 2022 07:00AM Can-Fite Reports Second Quarter 2022 Financial Results & Provides Clinical Update
Aug 23, 2022 07:00AM
Aug 22, 2022 07:00AM
Aug 17, 2022 07:26AM
Aug 17, 2022 07:25AM
Jul 11, 2022 07:01AM
Jul 11, 2022 07:00AM
Jun 29, 2022 07:00AM  Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis
Jun 24, 2022 07:00AM
Jun 9, 2022 07:01AM
Jun 9, 2022 07:00AM
May 26, 2022 07:00AM
May 16, 2022 07:00AM
May 2, 2022 07:00AM
Apr 5, 2022 07:00AM Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potential Complementary Product to its Phase III Oral Psoriasis Drug
Mar 28, 2022 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All